EEF1A2 and B-cell chronic lymphocytic leukemia: Indeed, our data show that blocking with JML-1 Ab could hinder CLL cell migration and adhesion as well as sTn-mediated downstream effects, which reinforces the therapeutic benefit of humanized Siglec-6 targeted antibodies.